- Home
- DSM vs PGEN Comparison
DSM vs PGEN Comparison
Compare DSM & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | PGEN |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 1.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | DSM | PGEN |
|---|---|---|
| Price | $6.14 | $4.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 84.7K | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.45 | $1.28 |
| 52 Week High | $6.30 | $5.47 |
Technical Indicators
Market Signals| Indicator | DSM | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 55.30 |
| Support Level | $6.13 | $3.96 |
| Resistance Level | $6.22 | $4.40 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 76.67 | 46.74 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.